Nov 23, 2020 | Brand Name Drugs, Generic Drugs, MedBen Access, MedBen Rx, Online Services, Prescription drugs, Rx Costs, Rx Facts, Savings
On December 1, MedBen Rx will roll out the new Member Prescription Portal. This easy-to-navigate site, available online through MedBen Access or via our mobile app, is designed to help members better manage their pharmacy plan and make cost-effective prescription drug...
Oct 16, 2020 | MedBen Rx, Prescription drugs, Rx Spending, Savings, Transparency
A National Alliance of Healthcare Purchaser Coalitions survey asked employers what they thought were the greatest threats to coverage affordability. Their responses… and how MedBen counters these concerns with proven saving solutions: Drug prices are a threat to...
Sep 5, 2020 | Prescription drugs, Specialty Drugs
Myalept tops the list of the most expensive drugs currently sold in the United States, as compiled by GoodRx. Used to treat leptin deficiency, Myalept carries a list price of $71,306 for a 30-day prescription. Mavenclad, a multiple sclerosis treatment, follows at...
Mar 6, 2020 | MedBen Rx, Prescription drugs
With the novel coronavirus COVID-19 a constant topic in the news nowadays, many consumers are stocking up on various drugs. MedBen is recommending no change to the current prescription drug refill guidelines for our clients and here’s why: Most wholesalers have a good...
Jan 7, 2020 | Cancer, Cholesterol, Prescription drugs, Statins, Wellness
According to American Heart Association, about 40 million adults in the U.S. take a statin to lower their cholesterol and reduce the risk for heart disease – and new research suggests that they might also be getting an added anti-cancer benefit. The study found that...
Nov 27, 2019 | Heart medications, Prescription drugs
At the annual meeting of the American Heart Association, researchers reported that patients who received drug therapy alone did not experience more heart attacks or die more often than those who also received bypass surgery or stents – further evidence that a...
